\contentsline {chapter}{Glossary}{xii}{section*.4}
\contentsline {chapter}{Acronyms}{xiii}{section*.6}
\contentsline {chapter}{\numberline {1}Introduction}{1}{chapter.1}
\contentsline {section}{\numberline {1.1}Cancer Research in the Post-Genomic Era}{1}{section.1.1}
\contentsline {subsection}{\numberline {1.1.1}Cancer as a Global Health Concern}{2}{subsection.1.1.1}
\contentsline {subsubsection}{\numberline {1.1.1.1}The Genetics and Molecular Biology of Cancers}{3}{subsubsection.1.1.1.1}
\contentsline {subsection}{\numberline {1.1.2}The Human Genome Revolution}{6}{subsection.1.1.2}
\contentsline {subsubsection}{\numberline {1.1.2.1}The First Human Genome Sequence}{6}{subsubsection.1.1.2.1}
\contentsline {subsubsection}{\numberline {1.1.2.2}Impact of Genomics}{7}{subsubsection.1.1.2.2}
\contentsline {subsection}{\numberline {1.1.3}Technologies to Enable Genetics Research}{7}{subsection.1.1.3}
\contentsline {subsubsection}{\numberline {1.1.3.1}DNA Sequencing and Genotyping Technologies}{7}{subsubsection.1.1.3.1}
\contentsline {subsubsection}{\numberline {1.1.3.2}Microarrays and Quantitative Technologies}{8}{subsubsection.1.1.3.2}
\contentsline {subsubsection}{\numberline {1.1.3.3}Massively Parallel ``Next Generation'' Sequencing}{9}{subsubsection.1.1.3.3}
\contentsline {subsubsubsection}{\numberline {1.1.3.3.1}Molecular Profiling with Genomics Technology}{11}{subsubsubsection.1.1.3.3.1}
\contentsline {subsubsubsection}{\numberline {1.1.3.3.2}Sequencing Technologies}{11}{subsubsubsection.1.1.3.3.2}
\contentsline {subsubsection}{\numberline {1.1.3.4}Bioinformatics as Interdisciplinary Genomic Analysis}{12}{subsubsection.1.1.3.4}
\contentsline {subsection}{\numberline {1.1.4}Follow-up Large-Scale Genomics Projects}{13}{subsection.1.1.4}
\contentsline {subsection}{\numberline {1.1.5}Cancer Genomes}{14}{subsection.1.1.5}
\contentsline {subsubsection}{\numberline {1.1.5.1}The Cancer Genome Atlas Project}{15}{subsubsection.1.1.5.1}
\contentsline {subsubsubsection}{\numberline {1.1.5.1.1}Findings from Cancer Genomes}{15}{subsubsubsection.1.1.5.1.1}
\contentsline {subsubsubsection}{\numberline {1.1.5.1.2}Genomic Comparisons Across Cancer Tissues}{17}{subsubsubsection.1.1.5.1.2}
\contentsline {subsubsubsection}{\numberline {1.1.5.1.3}Cancer Genomic Data Resources}{18}{subsubsubsection.1.1.5.1.3}
\contentsline {subsection}{\numberline {1.1.6}Genomic Cancer Medicine}{18}{subsection.1.1.6}
\contentsline {subsubsection}{\numberline {1.1.6.1}Cancer Genes and Driver Mutations}{18}{subsubsection.1.1.6.1}
\contentsline {subsubsection}{\numberline {1.1.6.2}Personalised or Precision Cancer Medicine}{19}{subsubsection.1.1.6.2}
\contentsline {subsubsubsection}{\numberline {1.1.6.2.1}Molecular Diagnostics and Pan-Cancer Medicine}{20}{subsubsubsection.1.1.6.2.1}
\contentsline {subsubsection}{\numberline {1.1.6.3}Targeted Therapeutics and Pharmacogenomics}{21}{subsubsection.1.1.6.3}
\contentsline {subsubsubsection}{\numberline {1.1.6.3.1}Targeting Oncogenic Driver Mutations}{21}{subsubsubsection.1.1.6.3.1}
\contentsline {subsubsection}{\numberline {1.1.6.4}Systems and Network Biology}{22}{subsubsection.1.1.6.4}
\contentsline {subsubsubsection}{\numberline {1.1.6.4.1} Network Medicine, and Polypharmacology}{24}{subsubsubsection.1.1.6.4.1}
\contentsline {section}{\numberline {1.2}A Synthetic Lethal Approach to Cancer Medicine}{25}{section.1.2}
\contentsline {subsection}{\numberline {1.2.1}Synthetic Lethal Genetic Interactions}{26}{subsection.1.2.1}
\contentsline {subsection}{\numberline {1.2.2}Synthetic Lethal Concepts in Genetics}{26}{subsection.1.2.2}
\contentsline {subsection}{\numberline {1.2.3}Studies of Synthetic Lethality}{27}{subsection.1.2.3}
\contentsline {subsubsection}{\numberline {1.2.3.1}Synthetic Lethal Pathways and Networks}{28}{subsubsection.1.2.3.1}
\contentsline {subsubsubsection}{\numberline {1.2.3.1.1}Evolution of Synthetic Lethality}{29}{subsubsubsection.1.2.3.1.1}
\contentsline {subsection}{\numberline {1.2.4}Synthetic Lethal Concepts in Cancer}{29}{subsection.1.2.4}
\contentsline {subsection}{\numberline {1.2.5}Clinical Impact of Synthetic Lethality in Cancer}{31}{subsection.1.2.5}
\contentsline {subsection}{\numberline {1.2.6}High{}-throughput Screening for Synthetic Lethality}{33}{subsection.1.2.6}
\contentsline {subsubsection}{\numberline {1.2.6.1}Synthetic Lethal Screens}{34}{subsubsection.1.2.6.1}
\contentsline {subsection}{\numberline {1.2.7}Computational Prediction of Synthetic Lethality}{37}{subsection.1.2.7}
\contentsline {subsubsection}{\numberline {1.2.7.1}Bioinformatics Approaches to Genetic Interactions}{37}{subsubsection.1.2.7.1}
\contentsline {subsubsection}{\numberline {1.2.7.2}Comparative Genomics}{38}{subsubsection.1.2.7.2}
\contentsline {subsubsection}{\numberline {1.2.7.3}Analysis and Modelling of Protein Data}{41}{subsubsection.1.2.7.3}
\contentsline {subsubsection}{\numberline {1.2.7.4}Differential Gene Expression}{43}{subsubsection.1.2.7.4}
\contentsline {subsubsection}{\numberline {1.2.7.5}Data Mining and Machine Learning}{44}{subsubsection.1.2.7.5}
\contentsline {subsubsection}{\numberline {1.2.7.6}Bimodality}{47}{subsubsection.1.2.7.6}
\contentsline {subsubsection}{\numberline {1.2.7.7}Rationale for Further Development}{48}{subsubsection.1.2.7.7}
\contentsline {section}{\numberline {1.3}E-cadherin as a Synthetic Lethal Target}{48}{section.1.3}
\contentsline {subsection}{\numberline {1.3.1}The \textit {CDH1} gene and it's Biological Functions}{48}{subsection.1.3.1}
\contentsline {subsubsection}{\numberline {1.3.1.1}Cytoskeleton}{49}{subsubsection.1.3.1.1}
\contentsline {subsubsection}{\numberline {1.3.1.2}Extracellular and Tumour Micro-Environment}{49}{subsubsection.1.3.1.2}
\contentsline {subsubsection}{\numberline {1.3.1.3}Cell-Cell Adhesion and Signalling}{49}{subsubsection.1.3.1.3}
\contentsline {subsection}{\numberline {1.3.2}\textit {CDH1} as a Tumour (and Invasion) Suppressor}{50}{subsection.1.3.2}
\contentsline {subsubsection}{\numberline {1.3.2.1}Breast Cancers and Invasion}{50}{subsubsection.1.3.2.1}
\contentsline {subsection}{\numberline {1.3.3}Hereditary Diffuse Gastric Cancer and Lobular Breast Cancer}{50}{subsection.1.3.3}
\contentsline {subsection}{\numberline {1.3.4}Somatic Mutations}{52}{subsection.1.3.4}
\contentsline {subsubsection}{\numberline {1.3.4.1}Mutation Rate}{52}{subsubsection.1.3.4.1}
\contentsline {subsubsection}{\numberline {1.3.4.2}Co-occurring Mutations}{52}{subsubsection.1.3.4.2}
\contentsline {subsection}{\numberline {1.3.5}Models of \textit {CDH1} loss in cell lines}{53}{subsection.1.3.5}
\contentsline {section}{\numberline {1.4}Summary and Research Direction of Thesis}{54}{section.1.4}
\contentsline {chapter}{\numberline {2}Methods and Resources}{58}{chapter.2}
\contentsline {section}{\numberline {2.1}Bioinformatics Resources for Genomics Research}{58}{section.2.1}
\contentsline {subsection}{\numberline {2.1.1}Public Data and Software Packages}{58}{subsection.2.1.1}
\contentsline {subsubsection}{\numberline {2.1.1.1}Cancer Genome Atlas Data}{59}{subsubsection.2.1.1.1}
\contentsline {subsubsection}{\numberline {2.1.1.2}Reactome and Annotation Data}{60}{subsubsection.2.1.1.2}
\contentsline {section}{\numberline {2.2}Data Handling}{60}{section.2.2}
\contentsline {subsection}{\numberline {2.2.1}Normalisation}{60}{subsection.2.2.1}
\contentsline {subsection}{\numberline {2.2.2}Sample Triage}{61}{subsection.2.2.2}
\contentsline {subsection}{\numberline {2.2.3}Metagenes and the Singular Value Decomposition}{63}{subsection.2.2.3}
\contentsline {subsubsection}{\numberline {2.2.3.1}Candidate Triage and Integration with Screen Data}{63}{subsubsection.2.2.3.1}
\contentsline {section}{\numberline {2.3}Techniques}{64}{section.2.3}
\contentsline {subsection}{\numberline {2.3.1}Statistical Procedures and Tests}{64}{subsection.2.3.1}
\contentsline {subsection}{\numberline {2.3.2}Gene Set Over-representation Analysis}{65}{subsection.2.3.2}
\contentsline {subsection}{\numberline {2.3.3}Clustering}{65}{subsection.2.3.3}
\contentsline {subsection}{\numberline {2.3.4}Heatmap}{66}{subsection.2.3.4}
\contentsline {subsection}{\numberline {2.3.5}Modeling and Simulations}{66}{subsection.2.3.5}
\contentsline {subsubsection}{\numberline {2.3.5.1}Receiver Operating Characteristic (Performance)}{67}{subsubsection.2.3.5.1}
\contentsline {subsection}{\numberline {2.3.6}Resampling Analysis}{67}{subsection.2.3.6}
\contentsline {section}{\numberline {2.4}Pathway Structure Methods}{68}{section.2.4}
\contentsline {subsection}{\numberline {2.4.1}Network and Graph Analysis}{68}{subsection.2.4.1}
\contentsline {subsection}{\numberline {2.4.2}Sourcing Graph Structure Data}{69}{subsection.2.4.2}
\contentsline {subsection}{\numberline {2.4.3}Constructing Pathway Subgraphs}{70}{subsection.2.4.3}
\contentsline {subsection}{\numberline {2.4.4}Network Analysis Metrics}{70}{subsection.2.4.4}
\contentsline {section}{\numberline {2.5}Implementation}{71}{section.2.5}
\contentsline {subsection}{\numberline {2.5.1}Computational Resources and Linux Utilities}{71}{subsection.2.5.1}
\contentsline {subsection}{\numberline {2.5.2}R Language and Packages}{72}{subsection.2.5.2}
\contentsline {subsection}{\numberline {2.5.3}High Performance and Parallel Computing}{75}{subsection.2.5.3}
\contentsline {chapter}{\numberline {3}Methods Developed During Thesis}{77}{chapter.3}
\contentsline {section}{\numberline {3.1}A Synthetic Lethal Detection Methodology}{77}{section.3.1}
\contentsline {section}{\numberline {3.2}Synthetic Lethal Simulation and Modelling}{80}{section.3.2}
\contentsline {subsection}{\numberline {3.2.1}A Model of Synthetic Lethality in Expression Data}{80}{subsection.3.2.1}
\contentsline {subsection}{\numberline {3.2.2}Simulation Procedure}{84}{subsection.3.2.2}
\contentsline {section}{\numberline {3.3}Detecting Simulated Synthetic Lethal Partners}{87}{section.3.3}
\contentsline {subsection}{\numberline {3.3.1}Binomial Simulation of Synthetic lethality}{87}{subsection.3.3.1}
\contentsline {subsection}{\numberline {3.3.2}Multivariate Normal Simulation of Synthetic lethality}{89}{subsection.3.3.2}
\contentsline {subsubsection}{\numberline {3.3.2.1}Multivariate Normal Simulation with Correlated Genes}{92}{subsubsection.3.3.2.1}
\contentsline {subsubsection}{\numberline {3.3.2.2}Specificity with Query-Correlated Pathways}{99}{subsubsection.3.3.2.2}
\contentsline {subsubsection}{\numberline {3.3.2.3}Importance of Directional Testing}{99}{subsubsection.3.3.2.3}
\contentsline {section}{\numberline {3.4}Graph Structure Methods}{101}{section.3.4}
\contentsline {subsection}{\numberline {3.4.1}Upstream and Downstream Gene Detection}{101}{subsection.3.4.1}
\contentsline {subsubsection}{\numberline {3.4.1.1}Permutation Analysis for Statistical Significance}{102}{subsubsection.3.4.1.1}
\contentsline {subsubsection}{\numberline {3.4.1.2}Hierarchy Based on Biological Context}{103}{subsubsection.3.4.1.2}
\contentsline {subsection}{\numberline {3.4.2}Simulating Gene Expression from Graph Structures}{104}{subsection.3.4.2}
\contentsline {section}{\numberline {3.5}Customised Functions and Packages Developed}{108}{section.3.5}
\contentsline {subsection}{\numberline {3.5.1}Synthetic Lethal Interaction Prediction Tool}{108}{subsection.3.5.1}
\contentsline {subsection}{\numberline {3.5.2}Data Visualisation}{109}{subsection.3.5.2}
\contentsline {subsection}{\numberline {3.5.3}Extensions to the iGraph Package}{112}{subsection.3.5.3}
\contentsline {subsubsection}{\numberline {3.5.3.1}Sampling Simulated Data from Graph Structures}{112}{subsubsection.3.5.3.1}
\contentsline {subsubsection}{\numberline {3.5.3.2}Plotting Directed Graph Structures}{112}{subsubsection.3.5.3.2}
\contentsline {subsubsection}{\numberline {3.5.3.3}Computing Information Centrality}{113}{subsubsection.3.5.3.3}
\contentsline {subsubsection}{\numberline {3.5.3.4}Testing Pathway Structure with Permutation Testing}{113}{subsubsection.3.5.3.4}
\contentsline {subsubsection}{\numberline {3.5.3.5}Metapackage to Install iGraph Functions}{114}{subsubsection.3.5.3.5}
\contentsline {chapter}{\numberline {4}Synthetic Lethal Analysis of Gene Expression Data}{115}{chapter.4}
\contentsline {section}{\numberline {4.1}Synthetic Lethal Genes in Breast Cancer}{116}{section.4.1}
\contentsline {subsection}{\numberline {4.1.1}Synthetic Lethal Pathways in Breast Cancer}{118}{subsection.4.1.1}
\contentsline {subsection}{\numberline {4.1.2}Expression Profiles of Synthetic Lethal Partners}{119}{subsection.4.1.2}
\contentsline {subsubsection}{\numberline {4.1.2.1}Subgroup Pathway Analysis}{122}{subsubsection.4.1.2.1}
\contentsline {section}{\numberline {4.2}Comparing Synthetic Lethal Gene Candidates}{125}{section.4.2}
\contentsline {subsection}{\numberline {4.2.1}Primary siRNA Screen Candidates}{125}{subsection.4.2.1}
\contentsline {subsection}{\numberline {4.2.2}Comparison with Correlation}{126}{subsection.4.2.2}
\contentsline {subsection}{\numberline {4.2.3}Comparison with Primary Screen Viability}{128}{subsection.4.2.3}
\contentsline {subsection}{\numberline {4.2.4}Comparison with Secondary siRNA Screen Validation}{129}{subsection.4.2.4}
\contentsline {subsection}{\numberline {4.2.5}Comparison to Primary Screen at Pathway Level}{131}{subsection.4.2.5}
\contentsline {subsubsection}{\numberline {4.2.5.1}Resampling Genes for Pathway Enrichment}{133}{subsubsection.4.2.5.1}
\contentsline {subsection}{\numberline {4.2.6}Integrating Synthetic Lethal Pathways and Screens}{136}{subsection.4.2.6}
\contentsline {section}{\numberline {4.3}Metagene Analysis}{138}{section.4.3}
\contentsline {subsection}{\numberline {4.3.1}Pathway Expression}{139}{subsection.4.3.1}
\contentsline {subsection}{\numberline {4.3.2}Somatic Mutation}{141}{subsection.4.3.2}
\contentsline {subsection}{\numberline {4.3.3}Synthetic Lethal Pathway Metagenes}{145}{subsection.4.3.3}
\contentsline {subsection}{\numberline {4.3.4}Synthetic Lethality in Breast Cancer}{146}{subsection.4.3.4}
\contentsline {section}{\numberline {4.4}Replication in Stomach Cancer}{147}{section.4.4}
\contentsline {section}{\numberline {4.5}Discussion}{148}{section.4.5}
\contentsline {subsection}{\numberline {4.5.1}Strengths of the SLIPT Methodology}{148}{subsection.4.5.1}
\contentsline {subsection}{\numberline {4.5.2}Synthetic Lethal Pathways for E-cadherin}{149}{subsection.4.5.2}
\contentsline {subsection}{\numberline {4.5.3}Replication and Validation}{151}{subsection.4.5.3}
\contentsline {subsubsection}{\numberline {4.5.3.1}Integration with siRNA Screening}{151}{subsubsection.4.5.3.1}
\contentsline {subsubsection}{\numberline {4.5.3.2}Replication across Tissues}{152}{subsubsection.4.5.3.2}
\contentsline {section}{\numberline {4.6}Summary}{152}{section.4.6}
\contentsline {chapter}{\numberline {5}Synthetic Lethal Pathway Structure}{154}{chapter.5}
\contentsline {section}{\numberline {5.1}Synthetic Lethal Genes in Reactome Pathways}{154}{section.5.1}
\contentsline {subsection}{\numberline {5.1.1}The PI3K/AKT Pathway}{155}{subsection.5.1.1}
\contentsline {subsection}{\numberline {5.1.2}The Extracellular Matrix}{157}{subsection.5.1.2}
\contentsline {subsection}{\numberline {5.1.3}G Protein Coupled Receptors}{160}{subsection.5.1.3}
\contentsline {subsection}{\numberline {5.1.4}Gene Regulation and Translation}{160}{subsection.5.1.4}
\contentsline {section}{\numberline {5.2}Network Analysis of Synthetic Lethal Genes}{161}{section.5.2}
\contentsline {subsection}{\numberline {5.2.1}Gene Connectivity and Vertex Degree}{162}{subsection.5.2.1}
\contentsline {subsection}{\numberline {5.2.2}Gene Importance and Centrality}{163}{subsection.5.2.2}
\contentsline {subsubsection}{\numberline {5.2.2.1}Information Centrality}{163}{subsubsection.5.2.2.1}
\contentsline {subsubsection}{\numberline {5.2.2.2}PageRank Centrality}{165}{subsubsection.5.2.2.2}
\contentsline {section}{\numberline {5.3}Relationships between Synthetic Lethal Genes}{167}{section.5.3}
\contentsline {subsection}{\numberline {5.3.1}Hierarchical Pathway Structure}{167}{subsection.5.3.1}
\contentsline {subsubsection}{\numberline {5.3.1.1}Contextual Hierarchy of PI3K}{167}{subsubsection.5.3.1.1}
\contentsline {subsubsection}{\numberline {5.3.1.2}Testing Contextual Hierarchy of Synthetic Lethal Genes}{167}{subsubsection.5.3.1.2}
\contentsline {subsection}{\numberline {5.3.2}Upstream or Downstream Synthetic Lethality}{171}{subsection.5.3.2}
\contentsline {subsubsection}{\numberline {5.3.2.1}Measuring Structure of Candidates within PI3K}{171}{subsubsection.5.3.2.1}
\contentsline {subsubsection}{\numberline {5.3.2.2}Resampling for Synthetic Lethal Pathway Structure}{173}{subsubsection.5.3.2.2}
\contentsline {section}{\numberline {5.4}Discussion}{175}{section.5.4}
\contentsline {section}{\numberline {5.5}Summary}{177}{section.5.5}
\contentsline {chapter}{\numberline {6}Simulation and Modeling of Synthetic Lethal Pathways}{179}{chapter.6}
\contentsline {section}{\numberline {6.1}Comparing Synthetic Lethal Detection Methods}{180}{section.6.1}
\contentsline {subsection}{\numberline {6.1.1}Performance of SLIPT and $\chi ^2$ across Quantiles}{181}{subsection.6.1.1}
\contentsline {subsubsection}{\numberline {6.1.1.1}Correlated Query Genes affects Specificity}{184}{subsubsection.6.1.1.1}
\contentsline {subsection}{\numberline {6.1.2}Alternative Synthetic Lethal Detection Strategies}{186}{subsection.6.1.2}
\contentsline {subsubsection}{\numberline {6.1.2.1}Correlation for Synthetic Lethal Detection}{187}{subsubsection.6.1.2.1}
\contentsline {subsubsection}{\numberline {6.1.2.2}Testing for Bimodality with BiSEp}{188}{subsubsection.6.1.2.2}
\contentsline {section}{\numberline {6.2}Simulations with Graph Structures}{189}{section.6.2}
\contentsline {subsection}{\numberline {6.2.1}Performance over a Graph Structure}{190}{subsection.6.2.1}
\contentsline {subsubsection}{\numberline {6.2.1.1}Simple Graph Structures}{190}{subsubsection.6.2.1.1}
\contentsline {subsubsection}{\numberline {6.2.1.2}Constructed Graph Structures}{191}{subsubsection.6.2.1.2}
\contentsline {subsection}{\numberline {6.2.2}Performance with Inhibitions}{195}{subsection.6.2.2}
\contentsline {subsection}{\numberline {6.2.3}Synthetic Lethality across Graph Structures}{201}{subsection.6.2.3}
\contentsline {subsection}{\numberline {6.2.4}Performance within a Simulated Human Genome}{204}{subsection.6.2.4}
\contentsline {section}{\numberline {6.3}Simulations in More Complex Graph Structures}{209}{section.6.3}
\contentsline {subsection}{\numberline {6.3.1}Simulations over Pathway-based Graphs}{210}{subsection.6.3.1}
\contentsline {subsection}{\numberline {6.3.2}Pathway Structures in a Simulated Human Genome}{213}{subsection.6.3.2}
\contentsline {section}{\numberline {6.4}Discussion}{216}{section.6.4}
\contentsline {subsection}{\numberline {6.4.1}Simulation Procedure}{216}{subsection.6.4.1}
\contentsline {subsection}{\numberline {6.4.2}Comparing Methods with Simulated Data}{217}{subsection.6.4.2}
\contentsline {subsection}{\numberline {6.4.3}Design and Performance of SLIPT}{218}{subsection.6.4.3}
\contentsline {subsection}{\numberline {6.4.4}Simulations from Graph Structures}{220}{subsection.6.4.4}
\contentsline {section}{\numberline {6.5}Summary}{221}{section.6.5}
\contentsline {chapter}{\numberline {7}Discussion}{223}{chapter.7}
\contentsline {section}{\numberline {7.1}Synthetic Lethality and \textit {CDH1} Biology}{223}{section.7.1}
\contentsline {subsection}{\numberline {7.1.1}Established Functions of \textit {CDH1}}{224}{subsection.7.1.1}
\contentsline {subsection}{\numberline {7.1.2}The Molecular Role of \textit {CDH1} in Cancer}{224}{subsection.7.1.2}
\contentsline {section}{\numberline {7.2}Significance}{225}{section.7.2}
\contentsline {subsection}{\numberline {7.2.1}Synthetic Lethality in the Genomic Era}{225}{subsection.7.2.1}
\contentsline {subsection}{\numberline {7.2.2}Clinical Interventions based on Synthetic Lethality}{227}{subsection.7.2.2}
\contentsline {section}{\numberline {7.3}Evaluating the Synthetic Lethality Prediction Tool}{228}{section.7.3}
\contentsline {subsection}{\numberline {7.3.1}Strength of the Synthetic Lethality Prediction Tool}{228}{subsection.7.3.1}
\contentsline {subsection}{\numberline {7.3.2}Limitations of the Synthetic Lethality Prediction Tool}{228}{subsection.7.3.2}
\contentsline {subsection}{\numberline {7.3.3}Comparisons to Alternative Methods}{228}{subsection.7.3.3}
\contentsline {subsubsection}{\numberline {7.3.3.1}Combined with Experimental Screening}{228}{subsubsection.7.3.3.1}
\contentsline {subsubsection}{\numberline {7.3.3.2}Differences to Computational Methods}{228}{subsubsection.7.3.3.2}
\contentsline {section}{\numberline {7.4}Future Directions}{228}{section.7.4}
\contentsline {subsection}{\numberline {7.4.1}Refinements Synthetic Lethality Prediction Methods}{230}{subsection.7.4.1}
\contentsline {subsubsection}{\numberline {7.4.1.1}Wider Use of Synthetic Lethality Prediction}{230}{subsubsection.7.4.1.1}
\contentsline {subsection}{\numberline {7.4.2}Validation of Synthetic Lethal Genes and Pathways}{230}{subsection.7.4.2}
\contentsline {subsubsection}{\numberline {7.4.2.1}Pre-clinical and Clinical Testing}{230}{subsubsection.7.4.2.1}
\contentsline {subsection}{\numberline {7.4.3}Application to Further Genes and Pathways}{230}{subsection.7.4.3}
\contentsline {chapter}{\numberline {8}Conclusion}{231}{chapter.8}
\contentsline {paragraph}{Aims}{232}{section*.109}
\contentsline {paragraph}{Summary}{233}{section*.110}
\contentsline {chapter}{\hbox to\@tempdima {\hfil }References}{235}{section.5.5}
\contentsline {chapter}{\numberline {A}Sample Quality}{261}{appendix.A}
\contentsline {section}{\numberline {A.1}Sample Correlation}{261}{section.A.1}
\contentsline {section}{\numberline {A.2}Replicate Samples in TCGA Breast}{264}{section.A.2}
\contentsline {chapter}{\numberline {B}Software Used for Thesis}{268}{appendix.B}
\contentsline {chapter}{\numberline {C}Mutation Analysis in Breast Cancer}{277}{appendix.C}
\contentsline {section}{\numberline {C.1}Synthetic Lethal Genes and Pathways}{277}{section.C.1}
\contentsline {section}{\numberline {C.2}Synthetic Lethal Expression Profiles}{280}{section.C.2}
\contentsline {section}{\numberline {C.3}Comparison to Primary Screen}{283}{section.C.3}
\contentsline {subsection}{\numberline {C.3.1}Resampling Analysis}{285}{subsection.C.3.1}
\contentsline {section}{\numberline {C.4}Compare SLIPT genes}{287}{section.C.4}
\contentsline {section}{\numberline {C.5}Metagene Analysis}{289}{section.C.5}
\contentsline {section}{\numberline {C.6}Expression of Somatic Mutations}{290}{section.C.6}
\contentsline {section}{\numberline {C.7}Metagene Expression Profiles}{293}{section.C.7}
\contentsline {chapter}{\numberline {D}Intrinsic Subtyping}{296}{appendix.D}
\contentsline {chapter}{\numberline {E}Stomach Expression Analysis}{298}{appendix.E}
\contentsline {section}{\numberline {E.1}Synthetic Lethal Genes and Pathways}{298}{section.E.1}
\contentsline {section}{\numberline {E.2}Comparison to Primary Screen}{302}{section.E.2}
\contentsline {subsection}{\numberline {E.2.1}Resampling Analysis}{304}{subsection.E.2.1}
\contentsline {section}{\numberline {E.3}Metagene Analysis}{306}{section.E.3}
\contentsline {chapter}{\numberline {F}Synthetic Lethal Genes in Pathways}{308}{appendix.F}
\contentsline {chapter}{\numberline {G}Pathway Connectivity for Mutation SLIPT}{316}{appendix.G}
\contentsline {chapter}{\numberline {H}Information Centrality for Gene Essentiality}{320}{appendix.H}
\contentsline {chapter}{\numberline {I}Pathway Structure for Mutation SLIPT}{323}{appendix.I}
